Patents by Inventor Michael R. McKeown
Michael R. McKeown has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11446309Abstract: The present invention provides methods for treating cancer using combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs.Type: GrantFiled: November 7, 2014Date of Patent: September 20, 2022Assignee: Dana-Farber Cancer Institute, Inc.Inventors: James E. Bradner, Michael R. McKeown, Margaret A. Shipp, Bjoern Chapuy, Kwok-kin Wong, Zhao Chen
-
Publication number: 20210100813Abstract: The present invention provides methods for treating cancer using combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs.Type: ApplicationFiled: July 16, 2020Publication date: April 8, 2021Inventors: James E. Bradner, Michael R. McKeown, Margaret A. Shipp, Bjoern Chapuy, Kwok Kin Wong, Zhao Chen
-
Patent number: 10793571Abstract: The present invention provides compounds of Formula (II) (e.g., compounds of Formula (I)), and pharmaceutically compositions thereof. Compounds of Formula (II) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits using the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.Type: GrantFiled: February 2, 2015Date of Patent: October 6, 2020Assignee: Dana-Farber Cancer Institute, Inc.Inventors: James E. Bradner, Nathanael S. Gray, Jun Qi, Michael R. McKeown, Dennis Buckley
-
Patent number: 10697025Abstract: The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists. The invention also provides packaged pharmaceutical compositions that comprise a RARA agonist and instructions for determining if such agonist is suitable for use in treatment.Type: GrantFiled: February 20, 2018Date of Patent: June 30, 2020Assignee: Syros Pharmaceuticals, Inc.Inventors: Mei W. Chen, Cindy Collins, Matthew L. Eaton, Matthew G. Guenther, Nan Ke, Jeremy Lopez, Michael R. McKeown, David A. Orlando
-
Patent number: 10167518Abstract: The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists. The invention also provides packaged pharmaceutical compositions that comprise a RARA agonist and instructions for determining if such agonist is suitable for use in treatment.Type: GrantFiled: October 31, 2017Date of Patent: January 1, 2019Assignee: Syros Pharmaceuticals, Inc.Inventors: Mei Wei Chen, Cindy Collins, Matthew Lucas Eaton, Matthew G. Guenther, Nan Ke, Jeremy Lopez, Michael R. Mckeown, David A. Orlando
-
Publication number: 20180187271Abstract: The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists. The invention also provides packaged pharmaceutical compositions that comprise a RARA agonist and instructions for determining if such agonist is suitable for use in treatment.Type: ApplicationFiled: February 20, 2018Publication date: July 5, 2018Inventors: Mei W. Chen, Cindy Collins, Matthew L. Eaton, Matthew G. Guenther, Nan Ke, Jeremy Lopez, Michael R. McKeown, David A. Orlando
-
Patent number: 9975896Abstract: The present invention provides novel compounds of any one of Formulae (I) to (IV), and pharmaceutically compositions thereof. Compounds of any one of Formulae (I) to (IV) are believed to be inhibitors of bromodomain-containing proteins (e.g., bromo and extra terminal proteins (BETs)). Also provided are methods, uses, and kits using the inventive compounds and pharmaceutical compositions for inhibiting the activity of the bromodomain-containing proteins and for treating and/or preventing in a subject in need thereof diseases associated with bromodomain-containing proteins, such as proliferative diseases.Type: GrantFiled: July 25, 2014Date of Patent: May 22, 2018Assignees: Dana-Farber Cancer Institute, Inc., University of MassachusettsInventors: Jason J. Marineau, James E. Bradner, Wei Zhang, Jun Qi, Michael R. McKeown, Harry Hongning Fu, Shuai Liu
-
Publication number: 20180087115Abstract: The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists. The invention also provides packaged pharmaceutical compositions that comprise a RARA agonist and instructions for determining if such agonist is suitable for use in treatment.Type: ApplicationFiled: October 31, 2017Publication date: March 29, 2018Inventors: Mei Wei Chen, Cindy Collins, Matthew Lucas Eaton, Matthew G. Guenther, Nan Ke, Jeremy Lopez, Michael R. McKeown, David A. Orlando
-
Patent number: 9845508Abstract: The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists. The invention also provides packaged pharmaceutical compositions that comprise a RARA agonist and instructions for determining if such agonist is suitable for use in treatment.Type: GrantFiled: June 2, 2016Date of Patent: December 19, 2017Assignee: Syros Pharmaceuticals, Inc.Inventors: Mei Wei Chen, Cindy Collins, Matthew Lucas Eaton, Matthew G. Guenther, Nan Ke, Jeremy Lopez, Michael R. McKeown, David A. Orlando
-
Patent number: 9695172Abstract: The present invention provides compounds of any one of Formulae (I), (II-C) (e.g., Formula (II)), and (III), and pharmaceutically compositions thereof. Compounds of any one of Formulae (I), (II-C), and (III) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits using the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.Type: GrantFiled: February 2, 2015Date of Patent: July 4, 2017Assignee: Dana-Farber Cancer Institute, Inc.Inventors: James E. Bradner, Nathanael S. Gray, Jun Qi, Michael R. McKeown, Dennis Buckley
-
Patent number: 9567301Abstract: The present invention provides compounds of Formula (I-A), (I-B), and (I-C), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting Myc (e.g., c-Myc) activity. The present invention further provides methods of using the compounds described herein for treating Myc-mediated disorders (e.g., cancer and other proliferative diseases). The present invention also provides assays for identifying Myc inhibitors.Type: GrantFiled: November 1, 2013Date of Patent: February 14, 2017Assignees: Dana-Farber Cancer Institute, Inc., Whitehead Institute for Biomedical ResearchInventors: James E. Bradner, Michael R. McKeown, Peter B. Rahl, Richard A. Young, Jason J. Marineau
-
Publication number: 20170008895Abstract: The present invention provides compounds of Formula (II) (e.g., compounds of Formula (I)), and pharmaceutically compositions thereof. Compounds of Formula (II) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits using the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.Type: ApplicationFiled: February 2, 2015Publication date: January 12, 2017Applicant: Dana-Farber Cancer Institute, Inc.Inventors: James E. Bradner, Nathanael S. Gray, Jun Qi, Michael R. McKeown, Dennis Buckley
-
Patent number: 9540320Abstract: The present invention provides compounds of Formula (I-A), (I-B), and (I-C), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting Myc (e.g., c-Myc) activity. The present invention further provides methods of using the compounds described herein for treating Myc-mediated disorders (e.g., cancer and other proliferative diseases). The present invention also provides assays for identifying Myc inhibitors.Type: GrantFiled: November 1, 2013Date of Patent: January 10, 2017Assignees: Dana-Farber Cancer Institute, Inc., Whitehead Institute for Biomedical ResearchInventors: James E. Bradner, Michael R. McKeown, Peter B. Rahl, Richard A. Young, Jason J. Marineau
-
Publication number: 20160355888Abstract: The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists. The invention also provides packaged pharmaceutical compositions that comprise a RARA agonist and instructions for determining if such agonist is suitable for use in treatment.Type: ApplicationFiled: June 2, 2016Publication date: December 8, 2016Inventors: Mei Wei Chen, Cindy Collins, Matthew Lucas Eaton, Matthew G. Guenther, Nan Ke, Jeremy Lopez, Michael R. McKeown, David A. Orlando
-
Publication number: 20160347750Abstract: The present invention provides compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) are binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits using the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.Type: ApplicationFiled: February 2, 2015Publication date: December 1, 2016Applicant: Dana-Farber Cancer Institute, Inc.Inventors: James E. Bradner, Nathanael S. Gray, Jun Qi, Michael R. McKeown, Dennis Buckley
-
Publication number: 20160347749Abstract: The present invention provides compounds of any one of Formulae (I), (II-C) (e.g., Formula (II)), and (III), and pharmaceutically compositions thereof. Compounds of any one of Formulae (I), (II-C), and (III) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits using the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.Type: ApplicationFiled: February 2, 2015Publication date: December 1, 2016Applicant: Dana-Farber Cancer Institute, Inc.Inventors: James E. Bradner, Nathanael S. Gray, Jun Qi Sharon, Michael R. Mckeown, Dennis Buckley
-
Publication number: 20160279141Abstract: The present invention provides methods for treating cancer using combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs.Type: ApplicationFiled: November 7, 2014Publication date: September 29, 2016Applicant: Dana-Farber Cancer Institute, Inc.Inventors: James E. Bradner, Michael R. McKeown, Margaret A. Shipp, Bjoern Chapuy, Kwok-kin Wong, Zhao Chen
-
Publication number: 20160168154Abstract: The present invention provides novel compounds of any one of Formulae (I) to (IV), and pharmaceutically compositions thereof. Compounds of any one of Formulae (I) to (IV) are believed to be inhibitors of bromodomain-containing proteins (e.g., bromo and extra terminal proteins (BETs)). Also provided are methods, uses, and kits using the inventive compounds and pharmaceutical compositions for inhibiting the activity of the bromodomain-containing proteins and for treating and/or preventing in a subject in need thereof diseases associated with bromodomain-containing proteins, such as proliferative diseases.Type: ApplicationFiled: July 25, 2014Publication date: June 16, 2016Applicants: Dana-Farber Cancer Institute, Inc., University of MassachusettsInventors: Jason J. Marineau, James E. Bradner, Wei Zhang, Jun Qi, Michael R. McKeown, Harry Hongning Fu, Shuai Liu
-
Publication number: 20150291521Abstract: The present invention provides compounds of Formula (I-A), (I-B), and (I-C), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting Myc (e.g., c-Myc) activity. The present invention further provides methods of using the compounds described herein for treating Myc-mediated disorders (e.g., cancer and other proliferative diseases). The present invention also provides assays for identifying Myc inhibitors.Type: ApplicationFiled: November 1, 2013Publication date: October 15, 2015Inventors: James E. Bradner, Michael R. McKeown, Peter B. Rahl, Richard A. Young, Jason J. Marineau